Mast buying Aires in all-stock deal, but raising cash anyway
This article was originally published in Scrip
Executive Summary
Mast Therapeutics will buy Aires Pharmaceuticals in an all-stock deal that values the acquired firm at about $5m. Mast also put in place a facility to raise new capital even though CEO Brian Culley noted that the company will not use its own cash to get Phase II data for the Aires drug candidate AIR001, which Novartis previously had an option to buy.
You may also be interested in...
Finance Watch: Canaan, Regeneron Reveal New Funds For Start-Ups
Private Company Edition: Regeneron launched a $500m venture fund and Canaan added $100m, bringing the venture firm’s recent total to $1bn-plus. Also, incubators plan to grow over the next decade and in recent financings Avenzo raised $150m and Nvelop launched with $100m.
Sage’s Dalzanemdor Prospects In Doubt After First Mid-Stage Readout
Dalzanemdor (SAGE-718) showed no difference from placebo in a Phase II Parkinson’s disease study, raising concerns about readouts later this year in Huntington’s and Alzheimer’s diseases.
First Phase III Depression Data For Intra-Cellular’s Caplyta Exceed Expectations
With positive results from the first Phase III trial of lumateperone in major depressive disorder and a second readout expected later this quarter, the company plans a supplemental filing in late 2024.